Cardiorenal Benefit of Tirzepatide in Type 1 Diabetes: A Case Report
Patients with type 1 diabetes (T1D) who are obese are at risk of cardiovascular disease, renal diseases, and other complications. Unfortunately, there is currently no cure for T1D, necessitating individuals with this condition to rely on lifelong insulin therapy. Tirzepatide, a dual-acting glucose-d...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer Medknow Publications
2024-10-01
|
| Edice: | Journal of Diabetology |
| Témata: | |
| On-line přístup: | https://journals.lww.com/jodb/fulltext/2024/15040/cardiorenal_benefit_of_tirzepatide_in_type_1.19.aspx |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|